Related videos
[ Ссылка ]
[ Ссылка ]
[ Ссылка ]
[ Ссылка ]
[ Ссылка ]
[ Ссылка ]
[ Ссылка ]
[ Ссылка ]
[ Ссылка ]
[ Ссылка ]
[ Ссылка ]

Sources
1. Cosmetics With KX-826 As The Main Ingredient Launch To Market_Kintor Pharmaceutical Limited. Accessed July 14, 2024. [ Ссылка ]
2. Pharma K. Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment of Male Androgenetic Alopecia in China. Accessed March 4, 2024. [ Ссылка ]
3. MarketScreener. Kintor Pharmaceutical Limited Announces Phase Ib/III Clinical Trial of KX-826 and Minoxidil Combination Therapy for the Treatment of Men Adults Receives Clearance by China NMPA -February 01, 2024 at 03:46 am EST | MarketScreener. Published February 1, 2024. Accessed February 29, 2024. [ Ссылка ]
4. BH07: Testosterone deficiency in men with female pattern hair loss | British Journal of Dermatology | Oxford Academic. Accessed November 28, 2023. [ Ссылка ]
5. Glaser R, Dimitrakakis C, Messenger A. Improvement in scalp hair growth in androgen-deficient women treated with testosterone: a questionnaire study. Br J Dermatol. 2012;166(2):274-278. doi:10.1111/j.1365-2133.2011.10655.x
6. Grandys M, Majerczak J, Frolow M, Sztefko K, Chlopicki S, Zoladz JA. Age-related decrease in serum dihydrotestosterone concentration is accompanied by impaired vascular status. Experimental Gerontology. 2023;173:112104. doi:10.1016/j.exger.2023.112104
7. Kintor Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US_Kintor Pharmaceutical Limited. Accessed May 12, 2023. [ Ссылка ]
8. Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5α-reductase inhibition in the treatment of male pattern hair loss: Results of a randomized placebo-controlled study of dutasteride versus finasteride. Journal of the American Academy of Dermatology. 2006;55(6):1014-1023. doi:10.1016/j.jaad.2006.05.007
9. Clinical Trial on Androgenetic Alopecia: KX0826, Placebo - Clinical Trials Registry - ICH GCP. Accessed April 12, 2021. [ Ссылка ]
10. Suzhou Kintor Pharmaceutical Inc,. A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Escalation Study in Healthy Male Subjects With Androgenetic Alopecia to Evaluate the Safety, Tolerability and PK of KX-826 Following Topical Multiple Dose Ascending. clinicaltrials.gov; 2021. Accessed April 11, 2021. [ Ссылка ]
11. Exclusive Interview | Interview of Senior Executives at Kintor Pharmaceutical. MYBIOGATE GLOBAL CHALLENGE. Published December 23, 2020. Accessed April 12, 2021. [ Ссылка ]
12. Limited KP. Kintor Pharmaceutical Limited Announces 2020 Business Progress and Annual Results. Accessed April 8, 2021. [ Ссылка ]
13. Results of Kintor’s Phase Ib Clinical Trials of Pyrilutamide in America_Kintor Pharmaceutical Limited. Accessed April 8, 2021. [ Ссылка ]

свернуть